Literature DB >> 30674544

Management of blood pressure in heart failure.

Ana Catarina Pinho-Gomes1,2, Kazem Rahimi1,2.   

Abstract

Hypertension is a common comorbidity in patients with heart failure and most drugs that have demonstrated to improve prognosis in this population have the potential to reduce blood pressure. Nonetheless, the relationship between blood pressure and clinical outcomes and the relevance of blood pressure reduction in heart failure remains unclear. This narrative review summarises the evidence currently available to guide blood pressure treatment in this patient group and highlights key questions for further research. In patients with heart failure with reduced ejection fraction, guidelines consensually recommend treating hypertension with drugs that have compelling indications in heart failure, with a target blood pressure of 130/80 mmHg. In patients with heart failure with preserved ejection fraction, guidelines acknowledge that the optimal treatment strategy remains unclear and thus recommend adopting a similar treatment strategy to patients with reduced ejection fraction. In any case, low blood pressure should not deter uptitration of drugs otherwise indicated to improve prognosis in heart failure, provided that patients tolerate drugs without adverse events. In the absence of evidence for modification of treatment efficacy and safety by baseline blood pressure, it is likely that treatment may actually lead to higher absolute risk reduction in patients with the lowest blood pressure. Special considerations and treatment adjustments are needed in the elderly as well as in patients with diabetes, chronic kidney disease and atrial fibrillation. More evidence is needed on blood pressure management in patients with heart failure in general, in whom the increasing burden of multimorbidity adds further complexity to treatment. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  heart failure; heart failure with preserved ejection fraction; heart failure with reduced ejection fraction; hypertension

Mesh:

Substances:

Year:  2019        PMID: 30674544     DOI: 10.1136/heartjnl-2018-314438

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  7 in total

1.  The Global Ambulatory Blood Pressure Monitoring (ABPM) in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry. Rationale, design and objectives.

Authors:  Miguel Camafort-Babkowski; Akintunde Adeseye; Antonio Coca; Albertino Damasceno; Giovanni De Simone; Maria Dorobantu; Pardeep S Jhund; Kazuomi Kario; Takahiro Komori; Hae Young Lee; Patricio López-Jaramillo; Okechukwu Ogah; Sandosh Padmanabahn; Domingo A Pascual-Figal; Wook Bum Pyun; Nicolás Federico Renna; Weimar Kunz Sebba Barroso; Osiris Valdez-Tiburcio; Fernando Stuardo Wyss-Quintana
Journal:  J Hum Hypertens       Date:  2020-11-25       Impact factor: 3.012

2.  Effect of miR-195-5p on cardiomyocyte apoptosis in rats with heart failure by regulating TGF-β1/Smad3 signaling pathway.

Authors:  Chun Xie; Huaxin Qi; Lei Huan; Yan Yang
Journal:  Biosci Rep       Date:  2020-05-29       Impact factor: 3.840

3.  Outcome assessment using estimation of left ventricular filling pressure in asymptomatic patients at risk for heart failure with preserved ejection fraction.

Authors:  Anna Bobenko; André Duvinage; Meinhard Mende; Volker Holzendorf; Kathleen Nolte; Christoph Herrmann-Lingen; Lutz Binder; Hans-Dirk Düngen; Gerd Hasenfuss; Burkert Pieske; Rolf Wachter; Frank Edelmann
Journal:  Int J Cardiol Heart Vasc       Date:  2020-05-07

4.  Genetic susceptibility, elevated blood pressure, and risk of atrial fibrillation: a Mendelian randomization study.

Authors:  Milad Nazarzadeh; Ana-Catarina Pinho-Gomes; Zeinab Bidel; Dexter Canoy; Abbas Dehghan; Karl Smith Byrne; Derrick A Bennett; George Davey Smith; Kazem Rahimi
Journal:  Genome Med       Date:  2021-03-04       Impact factor: 15.266

5.  A cardiac-null mutation of Prdm16 causes hypotension in mice with cardiac hypertrophy via increased nitric oxide synthase 1.

Authors:  Ji-One Kang; Tae Woong Ha; Hae-Un Jung; Ji Eun Lim; Bermseok Oh
Journal:  PLoS One       Date:  2022-07-21       Impact factor: 3.752

Review 6.  Targets and management of hypertension in heart failure: focusing on the stages of heart failure.

Authors:  Huanhuan Miao; Changhong Zou; Shijie Yang; Yook-Chin Chia; Minh Van Huynh; Guru Prasad Sogunuru; Jam Chin Tay; Tzung-Dau Wang; Kazuomi Kario; Yuqing Zhang
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-09       Impact factor: 2.885

Review 7.  Comparison of Hemodynamic Factors Predicting Prognosis in Heart Failure: A Systematic Review.

Authors:  Margot Aalders; Wouter Kok
Journal:  J Clin Med       Date:  2019-10-22       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.